Suppr超能文献

造血生长因子及其治疗用途。

Haematopoietic growth factors and their therapeutic use.

作者信息

Wadhwa Meenu, Thorpe Robin

机构信息

Cytokine and Growth Factor Section, Biotherapeutics Group, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 3QG, UK.

出版信息

Thromb Haemost. 2008 May;99(5):863-73.

Abstract

Haematopoietic growth factors constitute an important group of proteins that predominantly regulate the process of haematopoiesis. While some of these proteins have a very broad array of action on very early haematopoietic progenitors leading to multi-lineage increases in haematopoietic cell production and differentiation, others act in a restricted manner on specific committed terminally differentiated cell types. On the basis of their unique spectrum of activities, several factors are approved for clinical use in various indications while others are under investigation in the clinic either alone or as combination therapy. In this review, we have described factors which directly and in some cases indirectly influence haematopoiesis with particular focus on those factors which are either approved or show potential for clinical use. A brief description of the products that are currently available for clinical use is also provided. At present, several new products which include fusion proteins, peptide mimetics are either at the pre-clinical stage or in clinical development for various indications and these are also briefly described.

摘要

造血生长因子是一类重要的蛋白质,主要调节造血过程。其中一些蛋白质对非常早期的造血祖细胞具有非常广泛的作用,导致造血细胞生成和分化的多谱系增加,而其他蛋白质则以受限的方式作用于特定的终末分化细胞类型。基于其独特的活性谱,几种因子已被批准用于各种适应症的临床治疗,而其他因子正在临床中单独或作为联合疗法进行研究。在本综述中,我们描述了直接或在某些情况下间接影响造血的因子,特别关注那些已被批准或显示出临床应用潜力的因子。还简要介绍了目前可用于临床治疗的产品。目前,包括融合蛋白、肽模拟物在内的几种新产品正处于临床前阶段或针对各种适应症进行临床开发,本文也对这些产品进行了简要描述。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验